Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaborati ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

Booz Allen Hamilton Holding Corporation , the parent company of advanced technology company Booz Allen Hamilton Inc., will host a conference call at 8 a.m. EST on Friday, January 23, 2026, to discuss ...

Cardinal Health plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a ...

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not ...

(RTTNews) - Biotech stocks showed sharp moves in extended trading, with several names rebounding after steep regular-session losses. Fresh clinical data, FDA designations, and financing announcements ...

Compass Therapeutics ( ($CMPX) ) has issued an update. On January 6, 2026, Compass Therapeutics reported an estimated, unaudited cash and ...

Investing.com - Oppenheimer has upgraded Compass Pathways (NASDAQ:CMPS) from Perform to Outperform, setting a price target of $15.00 based on the potential of its psilocybin therapy for ...

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 ...

These inducement grants were approved by Compass Therapeutics Compensation Committee of the Board of Directors as a material inducement to employment. They were granted outside of the Company’s 2020 ...

Oppenheimer upgraded Compass Pathways (CMPS) to Outperform from Perform with a $15 price target The firm is citing it higher conviction that the company’s COMP360 will “lead the revolution of ...